Heart Drug Meets Anxious Mind: β-Blockers Found to Worsen Sleep After Stent Surgery

Millions of people undergo percutaneous coronary intervention each year, a procedure in which cardiologists thread catheters through blocked coronary arteries and restore blood flow with stents. For many patients, the surgery is a technical success: the chest pain resolves, the threatened heart muscle is reperfused, and complete revascularization is achieved. Yet a quieter problem often follows them home. In the weeks and months after the procedure, many patients report that their sleep has fallen apart, with difficulty falling asleep, frequent awakenings, and unrefreshing nights that undermine recovery. A new study published in BMC Psychiatry by Hengzhe Zhang, Daqing Li, and Xianfen Zhang now offers a striking clue about why this happens, and the answer lies in an unexpected interaction between two of the most common features of post-cardiac life: the β-blocker pills nearly every patient takes, and the anxiety that so often accompanies a heart diagnosis.

The research team set out to identify the factors that influence sleep quality in the early postoperative period after complete revascularization. They recruited 186 patients with coronary heart disease who had undergone interventional therapy and assessed them with a battery of standardized psychological and clinical scales during an outpatient follow-up visit three months after their procedure. This three-month window is clinically meaningful. It is late enough that the acute discomfort of the intervention has passed, but early enough that patients are still adjusting to a new medication regimen, a revised sense of their own mortality, and the daily reality of living with a chronically diseased heart. Sleep disturbances arising in this period can shape long-term adherence to cardiac rehabilitation, medication, and lifestyle change.

When the researchers ran their statistical models, two psychological variables emerged as independent negative predictors of sleep quality. Anxiety, with an odds ratio of 0.86 and a P value of 0.023, and depression, with an odds ratio of 0.81 and a P value of 0.009, both significantly predicted worse sleep. In practical terms, the higher a patient scored on measures of anxiety or depression, the more likely they were to report poor sleep quality, even after accounting for other clinical characteristics. This finding alone would not surprise cardiologists or psychiatrists, who have long recognized that mood disturbances are common after acute cardiac events and interventions. What came next, however, was far less expected.

The team turned to the PROCESS macro, a widely used statistical tool for probing interactions and conditional effects, to ask whether β-blocker use modified the relationship between anxiety and sleep. β-Blockers are a cornerstone of post-intervention cardiac care. They blunt the effects of adrenaline on the heart, lowering heart rate and blood pressure, reducing myocardial oxygen demand, and improving survival in many patients with coronary disease. The patients in this study were predominantly taking metoprolol, a lipophilic β-blocker that readily crosses the blood-brain barrier, a property long suspected to underlie its effects on sleep, dreams, and central nervous system symptoms. What the analysis revealed was a statistically significant interaction between β-blocker use and anxiety on sleep quality, with an odds ratio of 1.39 and a P value of 0.045. In these patients, β-blockers significantly amplified the negative impact of anxiety on sleep.

That interaction, however, was not uniform across the patient population, and this is where the study becomes genuinely thought-provoking. When the researchers stratified their sample by metabolic and disease-severity variables, a clear pattern of heterogeneity emerged. In patients with preserved metabolic function, defined by a HOMA-IR score below 2.5, a standard index of insulin resistance calculated from fasting glucose and insulin levels, β-blockers significantly intensified the sleep-disrupting effect of anxiety, with an odds ratio of 0.61 and a P value of 0.017. The same held true for patients with mild coronary lesions, assessed using the Gensini score, a widely used angiographic grading system in which scores below 33 indicate limited coronary disease. In this milder-disease group, the interaction was again significant, with an odds ratio of 0.57 and a P value of 0.027.

Just as telling were the groups in which the interaction vanished entirely. Among patients with insulin resistance, those with severe coronary lesions, and those suffering from depression, the amplifying effect of β-blockers on the anxiety-sleep relationship was not observed. The authors interpret this asymmetry as a paradox: intact physiological function may actually increase susceptibility to drug-psychological interactions. One plausible reading is that patients whose metabolisms and coronary anatomy are relatively preserved have more physiological reserve to spare, so the subtle central nervous system effects of a lipophilic β-blocker are not masked by the heavier burden of metabolic dysfunction or advanced disease. In sicker patients, by contrast, the dominant drivers of poor sleep may be the illness itself, insulin resistance, and depression, leaving less detectable room for the drug-anxiety interplay to express itself.

The pharmacology behind this interaction deserves attention. Metoprolol, unlike hydrophilic β-blockers such as atenolol, penetrates the central nervous system efficiently, where it can interfere with noradrenergic signaling involved in arousal and sleep-wake regulation. Lipophilic β-blockers have been associated in earlier literature with nightmares, vivid dreams, and sleep fragmentation. Anxiety, for its part, is characterized by hyperarousal, elevated sympathetic tone, and intrusive worry, all of which are hostile to the initiation and maintenance of sleep. The new findings suggest these two forces do not merely add together; they multiply. A patient whose sympathetic nervous system is already revved by anxiety may be particularly vulnerable to a drug that alters central adrenergic processing, producing sleep disruption greater than either factor alone would predict.

The clinical implications are immediate and practical. The authors advise that clinicians should monitor sleep quality when prescribing lipophilic β-blockers to metabolically healthier patients with mild coronary lesions. In an era when β-blockers are prescribed almost reflexively after coronary intervention, this is a call for more nuanced prescribing. It does not mean these patients should stop their medication, which remains protective for the heart, but it does mean that a routine question about sleep at follow-up visits could identify a modifiable problem early. Switching to a hydrophilic agent, adjusting the timing of the dose, or treating the anxiety itself are all strategies that might be weighed against the sleep findings, though the study was observational and exploratory and cannot establish that such changes would improve outcomes.

The authors are appropriately cautious about the limits of their work. The study was cross-sectional in design, relying on a single follow-up assessment rather than tracking patients over time, and it used subjective scales rather than objective measures such as polysomnography or actigraphy to capture sleep. The sample of 186 patients, while adequate for the statistical analyses performed, was drawn from a single clinical setting, and the subgroup analyses, though suggestive, involved smaller numbers and carry a risk of false-positive findings. The researchers themselves state that these exploratory findings require validation in prospective studies using objective sleep assessments. Until such studies are done, the interaction should be viewed as a hypothesis-generating signal rather than a settled fact.

Even with those caveats, the study opens a window onto an underappreciated dimension of cardiac recovery. The months after a stent procedure are a period of profound physiological and psychological recalibration, and the interplay between the drugs we give and the minds we treat may shape how well patients sleep, and by extension how well they heal. If a lipophilic β-blocker amplifies the sleep-destroying power of anxiety in precisely those patients who are otherwise healthiest, then the paradox the Chinese team describes is more than a statistical curiosity. It is a reminder that in modern cardiology, the heart and the brain are never treated in isolation, and that the prescription pad and the psychiatric interview may need to be read side by side.

Subject of Research: Interaction between β-blocker use and anxiety in early post-procedural sleep disorders after complete percutaneous coronary revascularization

Article Title: β-Blockers, anxiety, and sleep: an analysis of interactions in early sleep disorders following percutaneous complete revascularization

Article References: Zhang, H., Li, D., & Zhang, X. (2026). β-Blockers, anxiety, and sleep: an analysis of interactions in early sleep disorders following percutaneous complete revascularization. BMC Psychiatry. https://doi.org/10.1186/s12888-026-08659-w

Image Credits: AI Generated

DOI: 10.1186/s12888-026-08659-w

Keywords: β-blockers, anxiety, sleep quality, coronary heart disease, percutaneous coronary intervention, revascularization, metoprolol, insulin resistance, HOMA-IR, Gensini score, psychopharmacology, BMC Psychiatry